| Symbol | BMEA |
|---|---|
| Name | BIOMEA FUSION, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 900 MIDDLEFIELD ROAD,4TH FLOOR, REDWOOD CITY, California, 94063, United States |
| Telephone | +1 650 980-9099 |
| Fax | — |
| — | |
| Website | https://www.biomeafusion.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001840439 |
| Description | Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companys lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Additional info from NASDAQ: |
Faust Elizabeth 🟢 acquired 196.3K shares (1 derivative) of Biomea Fusion, Inc. (BMEA) at $1.15 Transaction Date: Jun 10, 2026 | Filing ID: 269470
Read moreAGUIAR ERIC 🟢 acquired 196.3K shares (1 derivative) of Biomea Fusion, Inc. (BMEA) at $1.15 Transaction Date: Jun 10, 2026 | Filing ID: 269469
Read moreRay Sumita 🟢 acquired 196.3K shares (1 derivative) of Biomea Fusion, Inc. (BMEA) at $1.15 Transaction Date: Jun 10, 2026 | Filing ID: 269468
Read moreAverill Julianne 🟢 acquired 173.7K shares (1 derivative) of Biomea Fusion, Inc. (BMEA) at $1.15 Transaction Date: Jun 10, 2026 | Filing ID: 269465
Read moreBiomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Read moreBiomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Read more(10% Negative) BIOMEA FUSION, INC. (BMEA) Announces Delay in results Trials for advancing to chronic clinical dosing Due to Patient Enrollment Issues, Regulatory Process, Safety Review
Read moreBiomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Read moreBiomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07502508 | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who A… | Phase2 | Type 2 Diabetes | Recruiting | 2026-04-30 | 2027-07-01 | ClinicalTrials.gov |
| NCT07502495 | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Ac… | Phase2 | Type 2 Diabetes | Recruiting | 2026-03-27 | 2027-07-01 | ClinicalTrials.gov |
| NCT07223216 | Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants | Phase1 | Obesity | Active_Not_Recruiting | 2025-10-23 | 2026-06-01 | ClinicalTrials.gov |
| NCT07254286 | Food Effect Study in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2025-09-11 | 2026-01-14 | ClinicalTrials.gov |
| NCT06152042 | Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus | Phase2 | Type 1 Diabetes Mellitus | Terminated | 2023-12-28 | 2025-07-18 | ClinicalTrials.gov |
| NCT05918692 | A Phase 1 Study of BMF-500 in Adults With Acute Leukemia | Phase1 | Acute Myeloid Leukemia | Active_Not_Recruiting | 2023-07-26 | 2026-04-01 | ClinicalTrials.gov |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven No… | Phase1 | Non Small Cell Lung Cancer | Terminated | 2023-01-12 | 2025-01-15 | ClinicalTrials.gov |
| NCT05731544 | Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Di… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2022-08-17 | 2025-07-08 | ClinicalTrials.gov |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (… | Phase1 | Acute Myeloid Leukemia | Terminated | 2022-01-24 | 2025-05-02 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| icovamenib 100 mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| BMF-219 | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |
| BMF-219 | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |
| BMF-219 | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |
| BMF-219 | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |
| BMF-219 | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |
| BMF-219 | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |
| BMF-219 | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |
| BMF-219 | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| icovamenib 100 mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| icovamenib 100mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| icovamenib 100 mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| icovamenib 100mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| icovamenib 100 mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| icovamenib 100mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| icovamenib 100 mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| icovamenib 100mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| icovamenib 100 mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| icovamenib 100mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| icovamenib 100 mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| icovamenib 100mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| BMF-219 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05631574 |
| BMF-219 | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT05153330 |
| BMF-219 | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |
| BMF-219 | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT05731544 |
| Icovamenib HPMC | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07254286 |
| Icovamenib | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07254286 |
| BMF-500 | Other | Phase PHASE1 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT05918692 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| icovamenib 100 mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| icovamenib 100mg | Other | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| BMF-650 | Other | Phase PHASE1 | Obesity | ACTIVE_NOT_RECRUITING | NCT07223216 |
| icovamenib 100 mg | DRUG | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| Placebo | DRUG | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| icovamenib 100mg | DRUG | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| Icovamenib HPMC | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07254286 |
| Icovamenib | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07254286 |
| BMF-650 | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT07223216 |
| BMF-500 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT05918692 |
| BMF-219 | DRUG | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |